[go: up one dir, main page]

CA2422882A1 - Vaccins adenoviraux de premiere generation evolues, exprimant les proteines gag, pol et nef du vih-1 a optimisation des codons et leurs modifications - Google Patents

Vaccins adenoviraux de premiere generation evolues, exprimant les proteines gag, pol et nef du vih-1 a optimisation des codons et leurs modifications Download PDF

Info

Publication number
CA2422882A1
CA2422882A1 CA002422882A CA2422882A CA2422882A1 CA 2422882 A1 CA2422882 A1 CA 2422882A1 CA 002422882 A CA002422882 A CA 002422882A CA 2422882 A CA2422882 A CA 2422882A CA 2422882 A1 CA2422882 A1 CA 2422882A1
Authority
CA
Canada
Prior art keywords
hiv
vector
adenovirus
nef
pol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002422882A
Other languages
English (en)
Inventor
Emilio A. Emini
Rima Youil
Andrew J. Bett
Ling Chen
David C. Kaslow
John W. Shiver
Timothy J. Toner
Danilo R. Casimiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2422882A1 publication Critical patent/CA2422882A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des vecteurs adénoviraux de première génération et des vaccins anti VIH à base adénovirale de recombinaison associés, qui présentent une meilleure stabilité et de meilleures propriétés de croissance, ainsi qu'une plus grande immunité à médiation cellulaire. Ces vecteurs adénoviraux sont utilisés afin créer et de produire, par culture cellulaire, divers vaccins anti VIH-1 à base adénovirale, qui contiennent des produits pharmaceutiques de polynucléotides gag du VIH-1, pol du VIH-1 et/ou nef du VIH-1, ainsi que des modifications, importantes d'un point de vue biologique, de ceux-ci. Ces vaccins adénoviraux, lorsqu'ils sont directement introduits dans un tissu de vertébré vivant, de préférence un hôte mammifère tel qu'un être humain ou un mammifère non humain d'importance vétérinaire commerciale ou domestique, expriment la protéine Gag, Pol et/ou Nef du VIH-1 ou une modification importante d'un point de vue biologique de celle-ci, ce qui induit une réponse immunitaire cellulaire qui reconnaît de manière spécifique le VIH-1. Les polynucléotides données à titre d'exemples sont des molécules d'ADN synthétisées qui codent la protéine Gag du VIH-1, qui codent la protéine Pol du VIH-1 à optimisation des codons, des dérivés de la protéine Pol du VIH-1 optimisée (y compris des constructions dans lesquelles l'activité de protéase, de transcriptase inverse, de RNase H et d'intégrase de Pol du VIH-1 est inactivée), la protéine Nef du VIH-1 et des dérivés de la protéine Nef du VIH-1 optimisée, y compris des mutants de nef qui effectuent des caractéristiques de type sauvage de Nef, telles que la myristylation et la régulation vers le bas de CD4 hôtes. Les vaccins adénoviraux selon cette invention, lorsqu'ils sont administrés seuls ou dans le cadre d'un régime à modalité combinée, offrent un avantage prophylactique à des individus non infectés précédemment et/ou assurent un effet thérapeutique en réduisant les niveaux de charge virale chez un individu infecté, ce qui permet de prolonger la phase asymptomatique de l'infection par le VIH-1.
CA002422882A 2000-09-15 2001-09-14 Vaccins adenoviraux de premiere generation evolues, exprimant les proteines gag, pol et nef du vih-1 a optimisation des codons et leurs modifications Abandoned CA2422882A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23318000P 2000-09-15 2000-09-15
US60/233,180 2000-09-15
PCT/US2001/028861 WO2002022080A2 (fr) 2000-09-15 2001-09-14 Vaccins adenoviraux de premiere generation evolues, exprimant les proteines gag, pol et nef du vih-1 a optimisation des codons et leurs modifications

Publications (1)

Publication Number Publication Date
CA2422882A1 true CA2422882A1 (fr) 2002-03-21

Family

ID=22876220

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002422882A Abandoned CA2422882A1 (fr) 2000-09-15 2001-09-14 Vaccins adenoviraux de premiere generation evolues, exprimant les proteines gag, pol et nef du vih-1 a optimisation des codons et leurs modifications

Country Status (5)

Country Link
EP (1) EP1320621A4 (fr)
JP (1) JP2004508064A (fr)
AU (2) AU2001294562B2 (fr)
CA (1) CA2422882A1 (fr)
WO (1) WO2002022080A2 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003516741A (ja) * 1999-12-17 2003-05-20 メルク エンド カムパニー インコーポレーテッド コドン最適化ＨＩＶ−１Ｎｅｆ及び修飾ＨＩＶ−１Ｎｅｆを発現するポリヌクレオチドワクチン
DK1436397T3 (da) 2001-10-11 2010-08-09 Merck Sharp & Dohme Hepatitis C virus vaccine
AU2002363189A1 (en) 2001-10-31 2003-05-12 The South African Medical Research Council Hiv-1 subtype isolate regulatory/accessory genes, and modifications and derivatives thereof
CA2478651A1 (fr) * 2002-03-13 2003-09-25 Merck & Co., Inc. Procede visant a induire une reponse immunitaire renforcee contre le vih
WO2003085138A1 (fr) 2002-03-29 2003-10-16 Merck & Co., Inc. Procedes de production de virus
US7326555B2 (en) 2002-05-14 2008-02-05 Merck & Co., Inc. Methods of adenovirus purification
CN1490056A (zh) * 2002-10-18 2004-04-21 ��¡���ɵ°��̲��о����� 针对hiv-1的免疫方法和组合物
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
WO2004037294A2 (fr) * 2002-10-23 2004-05-06 Crucell Holland B.V. Nouveaux parametres pour vaccins a base d'adenoviraux recombinants
AU2003298361B2 (en) 2002-12-17 2009-05-14 Crucell Holland B.V. Recombinant viral-based malaria vaccines
US7282365B2 (en) 2003-01-03 2007-10-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Rhesus HER2/neu, nucleotides encoding same, and uses thereof
RU2397249C2 (ru) 2003-07-21 2010-08-20 Иституто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа СИНТЕТИЧЕСКАЯ МОЛЕКУЛА НУКЛЕИНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР ДЛЯ КЛЕТОК МЛЕКОПИТАЮЩЕГО, КЛЕТКА МЛЕКОПИТАЮЩЕГО ХОЗЯИНА И СПОСОБ ЭКСПРЕССИИ ЧЕЛОВЕЧЕСКОГО БЕЛКА АНТИГЕНА ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА-2 (HER2/neu) ИЛИ ЕГО УКОРОЧЕННОЙ ФОРМЫ
GB2406336A (en) * 2003-09-24 2005-03-30 Oxxon Pharmaccines Ltd HIV Pharmaccines
EP1716173B8 (fr) 2004-02-11 2012-06-27 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Proteines de fusion a antigene carcinoembryonique et utilisations de ces proteines
JP2007522814A (ja) 2004-02-23 2007-08-16 クルセル ホランド ベー ヴェー ウイルスの精製方法
CN1972958B (zh) * 2004-04-12 2013-01-23 美国政府卫生与公共服务部 应用腺病毒载体诱导免疫应答的方法
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
AU2005293568B2 (en) 2004-10-13 2010-10-28 Beth Israel Deaconess Medical Center Inc. Improved adenoviral vectors and uses thereof
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
AU2012201827B2 (en) * 2005-05-12 2014-09-04 Glaxo Group Limited Vaccine composition
CN103088060A (zh) * 2005-05-12 2013-05-08 葛兰素集团有限公司 疫苗组合物
CA2623531C (fr) 2005-10-07 2013-12-10 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Vaccin de metalloproteinase 11 matricielle
LT2137210T (lt) * 2007-03-02 2016-12-27 Glaxosmithkline Biologicals Sa Naujas būdas ir kompozicijos
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
WO2009019612A2 (fr) 2007-08-03 2009-02-12 Institut Pasteur Vecteurs de transfert de gènes antiviraux et leurs applications médicinales
EP2047861B1 (fr) * 2007-10-12 2019-07-31 Institut Pasteur Vecteurs de transfert de gène de lentivirus convenant à une administration répétée et leurs applications médicinales
EP2185195A2 (fr) 2007-08-16 2010-05-19 Tripep Ab Plate-forme immunogène
ES2699685T3 (es) * 2008-11-18 2019-02-12 Beth Israel Deaconess Medical Ct Inc Vacunas antivíricas con inmunogenicidad celular mejorada
MX343037B (es) 2011-04-06 2016-10-20 Biovaxim Ltd Composiciones farmaceuticas para evitar y/o tratar una enfermedad de vih en humanos.
DK2825640T3 (en) 2012-03-12 2016-08-01 Crucell Holland Bv BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
EP4631509A2 (fr) 2012-11-16 2025-10-15 Beth Israel Deaconess Medical Center, Inc. Adénovirus recombinants et leur utilisation
SI3271729T1 (sl) 2015-03-18 2021-04-30 Janssen Vaccines & Prevention B.V. Testi za rekombinantne ekspresijske sisteme
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
AU2017283118B2 (en) 2016-06-20 2019-02-07 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
KR20200083510A (ko) 2017-10-31 2020-07-08 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 및 이의 용도
WO2019086461A1 (fr) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Vecteurs d'adénovirus et leurs utilisations
KR20200077559A (ko) 2017-10-31 2020-06-30 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 및 이의 용도
MX2020004488A (es) 2017-10-31 2020-08-13 Janssen Vaccines & Prevention Bv Adenovirus y usos de estos.
EP3723771A4 (fr) 2017-12-11 2022-04-06 Beth Israel Deaconess Medical Center, Inc. Adénovirus recombinés et leurs utilisations
CN111057716B (zh) * 2019-07-27 2022-04-15 中国人民解放军军事科学院军事医学研究院 用于包装重组人4型腺病毒的单质粒载体系统及其应用
IL291852A (en) 2019-10-03 2022-06-01 Janssen Vaccines & Prevention Bv Adenovirus vectors and their use
CN112522276B (zh) * 2020-12-15 2022-07-15 武汉纽福斯生物科技有限公司 一种emc1核苷酸序列及其应用
WO2025242657A1 (fr) 2024-05-21 2025-11-27 Shape Biopharmaceuticals Ag Blocs et agrégats de construction de lipopeptides
CN120158438A (zh) * 2024-10-14 2025-06-17 南京诺唯赞生物科技股份有限公司 Rna聚合酶变体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643579A (en) * 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
WO1996009399A2 (fr) * 1994-09-23 1996-03-28 Somatix Therapy Corporation Adenovirus chimerique permettant l'apport de genes
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
US6019978A (en) * 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
WO1996039178A1 (fr) * 1995-06-05 1996-12-12 The Wistar Institute Of Anatomy And Biology Recombinant humain du type 5 de l'adenovirus a deficience de replication, utilise comme porteur de vaccins
JP2001509375A (ja) * 1997-07-10 2001-07-24 ヘパヴェック アーゲー フュール ゲンテルアピエ 最小アデノウイルスベクターを作製するためのクローニングベクター
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO2000015819A1 (fr) * 1998-09-11 2000-03-23 The Children's Medical Center Corporation Lignees de cellules d'encapsidation pour particules de vecteur retroviral derive du vih
EP2206785A1 (fr) * 1998-12-31 2010-07-14 Novartis Vaccines and Diagnostics, Inc. Expression améliorée de polypeptides HIV et production de particules de type virus
GB9906177D0 (en) * 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
AU779951B2 (en) * 1999-12-22 2005-02-24 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized HIV-1 pol and modified HIV-1 pol
DE60026199T2 (de) * 2000-05-18 2006-11-23 Geneart Ag Synthetische Gene für gagpol und deren Verwendungen
CA2419822C (fr) * 2000-08-14 2011-02-08 Gary J. Nabel Modifications de env, gag, et pol de vih a pouvoir immunogene augmente aux fins d'immunisation genetique

Also Published As

Publication number Publication date
AU9456201A (en) 2002-03-26
EP1320621A4 (fr) 2005-11-23
WO2002022080A2 (fr) 2002-03-21
AU2001294562B8 (en) 2002-03-26
WO2002022080A9 (fr) 2003-03-06
WO2002022080A3 (fr) 2002-05-02
EP1320621A2 (fr) 2003-06-25
JP2004508064A (ja) 2004-03-18
WO2002022080A8 (fr) 2003-01-16
AU2001294562B2 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
AU2001294562B2 (en) Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized HIV1-Gag, Pol, Nef and Modifications
US20030044421A1 (en) Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications
AU2001294562A1 (en) Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized HIV1-Gag, Pol, Nef and Modifications
EP3385387B1 (fr) Séquences d'acide aminé et d'acide nucléique d'adénovirus simien, vecteurs les contenant, et utilisations afférentes
US7666427B2 (en) HIV vaccines based on Env of multiple clades of HIV
US20080254059A1 (en) Adenovirus Serotype 26 Vectors, Nucleic Acid and Viruses Produced Thereby
US20070054395A1 (en) Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications
US20080063656A1 (en) Adenoviral Vector Compositions
AU2003262790A1 (en) Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
CA2519207A1 (fr) Vecteurs adenoviraux serotype 34, acides nucleiques et virus produits par ces moyens
CN1972958B (zh) 应用腺病毒载体诱导免疫应答的方法
US20070077257A1 (en) Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications
US20060165664A1 (en) Method of inducing an enhanced immune response against hiv
WO2006086357A2 (fr) Vecteurs adenoviraux de serotype 36, acides nucleiques et virus ainsi produits
US20050106123A1 (en) Method of inducing an enhanced immune response against hiv

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead